Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mbx Biosciences Inc (MBX)

Mbx Biosciences Inc (MBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,691,458
  • Shares Outstanding, K 44,902
  • Annual Sales, $ 0 K
  • Annual Income, $ -61,920 K
  • EBIT $ -91 M
  • EBITDA $ -91 M
  • 60-Month Beta 0.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.16

Options Overview Details

View History
  • Implied Volatility 111.26% (-0.73%)
  • Historical Volatility 95.29%
  • IV Percentile 50%
  • IV Rank 14.51%
  • IV High 309.05% on 07/18/25
  • IV Low 77.70% on 10/24/25
  • Expected Move (DTE 11) 7.40 (20.00%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 6
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 3,461
  • Open Int (30-Day) 4,469
  • Expected Range 29.58 to 44.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.64
  • Number of Estimates 4
  • High Estimate -0.56
  • Low Estimate -0.70
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -36.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.58 +16.69%
on 01/12/26
44.89 -17.91%
on 01/15/26
+5.19 (+16.39%)
since 01/09/26
3-Month
23.07 +59.73%
on 11/14/25
44.89 -17.91%
on 01/15/26
+11.28 (+44.11%)
since 11/07/25
52-Week
4.81 +666.61%
on 04/07/25
44.89 -17.91%
on 01/15/26
+24.51 (+198.62%)
since 02/07/25

Most Recent Stories

More News
MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

CARMEL, Ind., Jan. 22, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision...

MBX : 36.87 (-2.12%)
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-week...

MBX : 36.87 (-2.12%)
MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

CARMEL, Ind., Dec. 15, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.87 (-2.12%)
MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.87 (-2.12%)
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Reported positive topline results from the Phase 2 Availâ„¢ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross...

MBX : 36.87 (-2.12%)
MBX Biosciences to Participate in November Investor Conferences

CARMEL, Ind., Oct. 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.87 (-2.12%)
MBX Biosciences, Inc. (MBX) Gets a Buy from Guggenheim

In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy rating on MBX Biosciences, Inc., with a price target of $84.00. The company’s shares closed last Friday at $16.69.Elevate...

MBX : 36.87 (-2.12%)
MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

CARMEL, Ind., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.87 (-2.12%)
MBX Biosciences Announces Pricing of Upsized Public Offering

CARMEL, Ind., Sept. 24, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies...

MBX : 36.87 (-2.12%)
Stock Indexes Post New Record Highs on AI Optimism

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.44%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.55%. December E-mini...

TER : 311.17 (+3.69%)
MSTR : 138.07 (+2.33%)
AMAT : 330.57 (+2.50%)
UAL : 116.33 (+0.36%)
AAPL : 274.14 (-1.34%)
DHI : 153.70 (-1.64%)
SRPT : 18.17 (-1.78%)
HP : 35.88 (-0.25%)
$IUXX : 25,270.58 (+0.78%)
COIN : 167.42 (+1.39%)
ASML : 1,430.00 (+1.20%)
ZNH26 : 112-050 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX...

See More

Key Turning Points

3rd Resistance Point 39.81
2nd Resistance Point 38.96
1st Resistance Point 38.32
Last Price 36.87
1st Support Level 36.83
2nd Support Level 35.98
3rd Support Level 35.34

See More

52-Week High 44.89
Last Price 36.87
Fibonacci 61.8% 29.58
Fibonacci 50% 24.85
Fibonacci 38.2% 20.12
52-Week Low 4.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar